Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection.

COVID-19 SARS-CoV-2 antibodies neutralization seasonal coronavirus

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
07 09 2021
Historique:
received: 08 10 2020
accepted: 01 12 2020
pubmed: 4 12 2020
medline: 4 12 2020
entrez: 3 12 2020
Statut: ppublish

Résumé

Cross-reactive immune responses elicited by seasonal coronaviruses might affect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) susceptibility and disease outcomes. We measured neutralizing activity against SARS-CoV-2 in prepandemic sera from patients with prior polymerase chain reaction scan-confirmed seasonal coronavirus infection. Although neutralizing activity against seasonal coronaviruses was detected in nearly all sera, cross-reactive neutralizing activity against SARS-CoV-2 was undetectable.

Identifiants

pubmed: 33270134
pii: 6017810
doi: 10.1093/cid/ciaa1803
pmc: PMC7799301
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1208-e1211

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI078788
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : R37AI640003
Organisme : NIAID NIH HHS
ID : F30 AI157898
Pays : United States
Organisme : NIH HHS
ID : T32GM007739
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007739
Pays : United States

Commentaires et corrections

Type : UpdateOf
Type : CommentIn

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
J Clin Microbiol. 2010 Aug;48(8):2940-7
pubmed: 20554810
Science. 2020 Aug 7;369(6504):731-736
pubmed: 32540900
Nat Med. 2020 Nov;26(11):1691-1693
pubmed: 32929268
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Am J Med. 2015 Nov;128(11):1251.e11-20
pubmed: 26087047
J Clin Virol. 2012 Feb;53(2):135-9
pubmed: 22188723
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939

Auteurs

Daniel Poston (D)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, New York, NY, USA.

Yiska Weisblum (Y)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.

Helen Wise (H)

Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom.

Kate Templeton (K)

Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom.

Sara Jenks (S)

Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, United Kingdom.

Theodora Hatziioannou (T)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.

Paul Bieniasz (P)

Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA.

Classifications MeSH